After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...
Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...
News Medical on MSN2d
Scientists map cancer mutations in EGFR gene, revealing drug resistance pathsResearchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
Researchers used the Parsortix® system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC that were undergoing treatment with osimertinib (TAGRISSO: AstraZeneca). Osimertinib is ...
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback